Australia's most trusted
source of pharma news
Friday, 08 August 2025
Posted 7 August 2025 AM
The TGA accepted seven innovative medicines for review in June, including Novartis’ long-lost lung cancer treatment Tabrecta initially filed three years ago.
Tabrecta was filed with the TGA under orphan status in June 2022 for the treatment of non-small cell lung cancer with genetic MET alterations but never made it over the line, disappearing from the regulator’s review list in the following year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.